購読する
モデル製品
サービス
前臨床薬効評価
コミュ二ティー
Col7a1 KO Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
Col7a1 KO Mouse
製品名
Col7a1 KO Mouse
製品ID
C001539
系統名
C57BL/6JCya-Col7a1em3/Cya
背景情報
C57BL/6JCya
状況
このマウス系統を論文で使用する場合は、「Col7a1 KO Mouse(カタログ番号C001539)はサイアジェンから購入しました。」と引用してください。
Disease Animal Models
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
Disease Animal Models
基本情報
検証 Data
関連リソース
基本情報
遺伝子名
遺伝子別名
--
NCBI ID
染色体
Chr 9
MGI ID
さらに
系統詳細
Epidermolysis Bullosa (EB) is a genetic skin disease characterized by the formation of blisters and bullae on the skin and mucous membranes following minor trauma or friction. Common clinical symptoms include the appearance of blisters, blood blisters, and erosion on the skin. Depending on the site of onset, hereditary EB can be divided into three types: Simplex Epidermolysis Bullosa (EBS), Junctional Epidermolysis Bullosa (JEB), and Dystrophic Epidermolysis Bullosa (DEB). Mutations in the COL7A1 gene are the cause of Dystrophic Epidermolysis Bullosa (DEB), and the different clinical phenotypes presented by DEB are related to the mutation site and form of the COL7A1 gene. The COL7A1 gene encodes type VII collagen protein, which forms anchoring fibrils that bind the dermal tissue to the epidermal tissue. Functional deficiency of anchoring fibrils caused by COL7A1 mutations makes the patient's skin extremely fragile, easily causing blisters or tears due to minor friction or trauma. To date, at least 324 pathogenic mutations related to DEB have been found in the COL7A1 gene, including nonsense, missense, deletion, insertion, splicing, and regulatory mutations [1]. Research shows that Col7a1 gene homozygous knockout mice exhibit high mortality after birth, with hemorrhagic blisters appearing on the palms of the forepaws and hind paws within 24-48 hours, followed by severe RDEB symptoms [2]. This is one of the commonly used preclinical models for DEB research.
Col7a1 knockout (KO) mice, constructed by using gene editing technology to knock out the homologous gene Col7a1 of human COL7A1 in mice, serve as a research model for Dystrophic Epidermolysis Bullosa (DEB). Homozygous Col7a1 KO mice lack the expression of the Col7a1 gene and COL7A1 protein, and exhibit symptoms of skin redness and blistering on the palms of the fore and hind paws on the first day after birth, and die within three days after birth. Histological examination results show that the skin of Col7a1 KO mice exhibits significant subcutaneous edema, and there is a separation between the epidermis and dermis, which is roughly the same as the pathogenesis and pathological characteristics of human Dystrophic Epidermolysis Bullosa (DEB) in the clinic. Therefore, Col7a1 KO mice can be used for the mechanistic study of Dystrophic Epidermolysis Bullosa (DEB), as well as the development, screening, and evaluation of therapeutic drugs.
参考文献
Dang N and Murrell DF. Mutation Analysis and Characterization of COL7A1 Mutations in Dystrophic Epidermolysis Bullosa. Exp Dermatol 2008;17(7) 553-568.
Fritsch A, Loeckermann S, Kern JS, Braun A, Bösl MR, Bley TA, Schumann H, von Elverfeldt D, Paul D, Erlacher M, Berens von Rautenfeld D, Hausser I, Fässler R, Bruckner-Tuderman L. A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J Clin Invest. 2008 May;118(5):1669-79.
系統作製戦略
The Col7a1 gene is located on chromosome 9 of the mouse, comprising a total of 119 exons. Gene editing technology is used to knock out the 4th to 13th exon region of this gene.

Figure 1. Diagram of the gene editing strategy for the generation of Col7a1 KO mice.
適用分野
Col7a1 KO mice can be used for the mechanistic study of Dystrophic Epidermolysis Bullosa (DEB), as well as the development, screening, and evaluation of therapeutic drugs.
検証 Data
関連リソース
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
